Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and Low Dose Ara-C in High Risk MDS
NCT00776503Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- May 2008
- Primary completion
- Nov 2011
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Started May 2008; status: completed.
02
Drugs
vorinostat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00776503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00776503.